Francesco Costacurta

Innsbruck Medical University — Austria

Medicine · Health Sciences

9h-index429citations17works4.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(13), Computational Drug Discovery Methods(9), vaccines and immunoinformatics approaches(7), Virus-based gene therapy research(4), Mosquito-borne diseases and control(2)

Publications17 total

A novel dual-chimeric surrogate virus to select, test and characterize mutants of protease and glycoprotein inhibitors.
2026Open Access
Improving the safety of gain-of-function research for antiviral resistance profiling against spike and M pro inhibitors using a dual-chimeric surrogate virus
Zenodo (CERN European Organization for Nuclear Research)·2026Open Access
Improving the safety of gain-of-function research for antiviral resistance profiling against spike and M pro inhibitors using a dual-chimeric surrogate virus
Zenodo (CERN European Organization for Nuclear Research)·2026Open Access
Using Vesicular Stomatitis Virus as a Platform for Directed Protease Evolution
Current Protocols·2024· 1 citedOpen Access
Vesicular Stomatitis Virus as a Platform for Protease Activity Measurements
Current Protocols·2024· 1 citedOpen Access
A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system
PLoS Pathogens·2024· 10 citedOpen Access
Highly specific SARS-CoV-2 main protease (Mpro) mutations against the clinical antiviral ensitrelvir selected in a safe, VSV-based system
Antiviral Research·2024· 9 citedOpen Access
Study of key residues in MERS-CoV and SARS-CoV-2 main proteases for resistance against clinically applied inhibitors nirmatrelvir and ensitrelvir
npj Viruses·2024· 13 citedOpen Access
Highly Specific Sars-Cov-2 Main Protease (Mpro) Mutations Against the Clinical Antiviral Ensitrelvir Selected in a Safe, Vsv-Based System
SSRN Electronic Journal·2024· 2 citedOpen Access
Identification of key residues in MERS-CoV and SARS-CoV-2 main proteases for resistance against clinically applied inhibitors nirmatrelvir and ensitrelvir
2023· 2 citedOpen Access
A comprehensive study of SARS-CoV-2 main protease (M <sup>pro</sup> ) inhibitor-resistant mutants selected in a VSV-based system
2023· 9 citedOpen Access
A comprehensive study of SARS-CoV-2 main protease (M pro ) inhibitor-resistant mutants selected in a VSV-based system
Zenodo (CERN European Organization for Nuclear Research)·2023Open Access
Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors
Science Advances·2023· 164 citedOpen Access
SARS-CoV-2 3CL <sup>pro</sup> mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376
Science Translational Medicine·2022· 131 citedOpen Access
Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors
2022· 42 citedOpen Access
SARS-CoV-2 3CLpro mutations confer resistance to Paxlovid (nirmatrelvir/ritonavir) in a VSV-based, non-gain-of-function system
2022· 14 citedOpen Access
A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition
Communications Biology·2022· 31 citedOpen Access

Frequent Co-authors

Emmanuel Heilmann(17), Dorotheé von Laer(14), Stefanie Rauch(11), Seyed Arad Moghadasi(8), David Bante(8), Reuben S. Harris(7), Laura Krismer(7), Helge Schöppe(7), Anna Sauerwein(7), Teresa Kaserer(7), Bernhard Sprenger(6), Andrea Dodaro(6), Anne Heberle(5), Toni Rabensteiner(5), Matteo Pavan(4), Davide Bassani(4), Stefano Moro(4), Bernhard Rupp(4), Andreas Naschberger(4), Chengjin Ye(3)